Fibrosing cholestatic hepatitis as a variant of the course of hepatotropic viruses’ infection

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Fibrosing cholestatic hepatitis is a special variant of infectious hepatitis, with a rapid progressive deterioration of liver function, and usually results in immunosuppression. It has also been reported in patients with immunocompetent status having viral hepatitis B and C. Fibrosing cholestatic hepatitis is diagnosed based on the histological examination of the liver tissue, which reveals severe damage to hepatocytes with pronounced ballooning over a weak inflammatory reaction, pericellular and perisinusoidal fibrosis, and intracellular and tubular cholestases. Analysis of the literature confirms the authors’ assumption that pathological changes in the liver, described as fibrosing cholestatic hepatitis, can develop in different conditions under the influence of various infectious agents. Despite the availability of effective antiviral therapy for hepatitis B and C, the outcomes of fibrosing cholestatic hepatitis are often unfavorable, particularly in cases not associated with solid-organ transplantation. Currently, because of the emergence of numerous drugs that selectively act on the immune system and the development of new areas of medicine such as hematology, rheumatology, oncology, transplantology, and infectious diseases, doctors in these specialties increasingly encounter severe liver damage in patients receiving specific therapy. The authors believe that doctors who do not work at liver transplantation centers underestimate the possibility of fibrosing cholestatic hepatitis development in patients with viral hepatitis B and C, in the clinic of infectious and internal diseases.

About the authors

Vladimir E. Syutkin

N.V. Sklifosovsky Research Institute of Emergency Medical Care

Author for correspondence.
Email: vladsyutkin@gmail.com
ORCID iD: 0000-0001-8391-5211
SPIN-code: 5011-6287

MD, Dr. Sci. (Medicine)

Russian Federation, Moscow

Vladimir P. Chulanov

National Medical Research Center for Phthisiopulmonology and Infectious Diseases

Email: vladimir@chulanov.ru
ORCID iD: 0000-0001-6303-9293
SPIN-code: 2336-4545

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

References

  1. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi: 10.1002/hep.29800
  2. European Association for the Study of the Liver. EASL 2017. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi: 10.1016/j.jhep.2017.03.021
  3. Syutkin VE, Andreytzeva OA, Kozlova AV, Chzhao AV. De novo HBV infection in individuals with a history of liver transplantation due to disease not associated with viral hepatitis B (case analysis). Infektsionnye bolezni. 2009;7(4):75–79. (In Russ). EDN: MBDFHV
  4. Lenggenhager D, Weber A. Hepatitis E Virus and the Liver: Clinical Settings and Liver Pathology. Gastroenterology Clinics of North America. 2017;46(2):393–407. doi: 10.1016/j.gtc.2017.01.010
  5. Davies SE, Portmann BC, O’Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991;13(1):150–157.
  6. O’Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992;14(1):104–111. doi: 10.1016/0168-8278(92)90138-f
  7. Schluger LK, Sheiner PA, Thung SN, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology. 1996;23(5):971–976. doi: 10.1002/hep.510230505
  8. Lim HL, Lau GK, Davis GL, Dolson, DJ, Lau JY, Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. Gastroenterology. 1994;106(1):248–251. doi: 10.1016/s0016-5085(94)95829-7
  9. Duseja A, Nada R, Kalra N, et al. Fibrosing cholestatic hepatitis-like syndrome in a hepatitis B virus and hepatitis C virus-negative renal transplant recipient: a case report with autopsy findings. Tropical Gastroenterology. 2003;24(1):31–34.
  10. Agarwal SK, Kalra V, Dinda A, et al. Fibrosing cholestatic hepatitis in renal transplant recipient with CMV infection: a case report. International Urology and Nephrology. 2004;36(3):433–435. doi: 10.1007/s11255-004-6196-9
  11. Duseja A, Das A, Chawla YK, Bhansali A, Sakhuja V. Clinicopathological conference: fibrosing cholestatic hepatitis presenting as subacute hepatic failure in a non-transplant patient. Dig Dis Sci. 2009; 54(11):2341–2345. doi: 10.1007/s10620-009-0878-1
  12. Muñoz de Bustillo E, Benito A, et al. Fibrosing cholestatic hepatitis-like syndrome in hepatitis B virus-negative and hepatitis C virus-negative renal transplant recipients. Am J Kidney Dis. 2001;38(3):640–645. doi: 10.1053/ajkd.2001.26902
  13. Shan YS, Lee PC, Wang JR, et al. Fibrosing cholestatic hepatitis possibly related to persistent parvovirus B19 infection in a renal transplant recipient. Nephrol Dial Transplant. 2001;16(12): 2420–2422. doi: 10.1093/ndt/16.12.2420
  14. Longerich T, Haferkamp K, Tox U, Schirmacher P. Acute liver failure in a renal transplant patient caused by adenoviral hepatitis superimposed on a fibrosing cholestatic hepatitis B. Human pathology. 2004;35(7):894–897. doi: 10.1016/j.humpath.2004.04.004
  15. Xiao SY, Lu L, Wang HL. Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis. International Journal of Clinical and Experimental Pathology. 2008;1(5):396–402.
  16. Hori T, Onishi Y, Kamei H, et al. Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation. Ann Gastroenterol. 2016;29(4):454–459. doi: 10.20524/aog.2016.0069
  17. Chzhao AV, Andreitseva OI, Syutkin VE, et al. Success of early antiviral monotherapy with pegylated interferon α-2a for posttransplantation fibrosing cholestatic hepatitis C (a clinical case). Transplantologiya. The Russian Journal of Transplantation. 2011;(2-3):69–74. (In Russ). doi: 10.23873/2074-0506-2011-0-2-3-69-74
  18. De Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant. 2006;6(12):2983–2993. doi: 10.1111/j.1600-6143.2006.01546.x
  19. Sutherland N, Li Wai Suen CFD, Mills C, Lokan J, Sinclair M Fibrosing Cholestatic Hepatitis-Like Syndrome in an Immunocompetent Patient With an Acute Flare of Chronic Hepatitis B. Hepatology. 2019;70(4):1480–1483. doi: 10.1002/hep.30763
  20. Philips CA, Paramaguru R, Rajesh S, et al. An unusual cause of acute-on-chronic liver failure. Indian Journal of Gastroenterology. 2019;38(3):278–279. doi: 10.1007/s12664-019-00963-6
  21. Akagi H, Mizuki A, Tominaga T, et al. [Acute hepatitis C infection with prolonged intrahepatic cholestasis and remarkable progression of fibrosis mimicking fibrosing cholestatic hepatitis]. Nihon Shokakibyo Gakkai Zasshi. 2014;111(6):1141–1148. (In Japanese).
  22. Wong PN, Fung TT, Chan AN, et al. Unusual case of hepatitic cholestasis resembling fibrosing cholestatic hepatitis in a dialysis patient with chronic hepatitis B infection. J Gastroenterol Hepatol. 2006;21(10):1635–1637. doi: 10.1111/j.1440-1746.2006.04340.x
  23. Fang JW, Wright TL, Lau JY. Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet. 1993;342(8880):1175. doi: 10.1016/0140-6736(93)92160-u
  24. Poulet B, Chapel F, Dény P, et al. Hépatite cholestatique et fibrosante par réactivation virale B au cours du SIDA. Annales de pathologie. 1996;16(3):188–191. (In French).
  25. Rosenberg PM, Farrell JJ, Abraczinskas DR, et al. Rapidly progressive fibrosing cholestatic hepatitis-hepatitis C virus in HIV coinfection. Am J Gastroenterol. 2002;97(2):478–483. doi: 10.1111/j.1572-0241.2002.05459.x
  26. Moreno A, Moreno A, Pérez-Elías MJ, et al. Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature. Human pathology. 2006;37(10):1344-1349. doi: 10.1016/j.humpath.2006.05.003
  27. Lee HK, Yoon GS, Min KS, et al. Fibrosing cholestatic hepatitis: a report of three cases. J Korean Med Sci. 2000;15(1):111–114. doi: 10.3346/jkms.2000.15.1.111
  28. Kojima H, Abei M, Takei N, et al. Fatal reactivation of hepatitis B virus following cytotoxic chemotherapy for acute myelogenous leukemia: fibrosing cholestatic hepatitis. Eur J Haematol. 2002; 69(2):101–104. doi: 10.1034/j.1600-0609.2002.02719.x
  29. Jung S, Lee HC, Han JM, et al. Four cases of hepatitis B virus-related fibrosing cholestatic hepatitis treated with lamivudine. J Gastroenterol Hepatol. 2002;17(3):345–350. doi: 10.1046/j.1440-1746.2002.02600.x
  30. Wasmuth JC, Fischer HP, Sauerbruch T, Dumoulin FL. Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-Hodgkin’s lymphoma. Eur J Med Res. 2008;13(10):483–486.
  31. Zanati SA, Locarnini SA, Dowling JP, et al. Hepatic failure due to fibrosing cholestatic hepatitis in a patient with pre-surface mutant hepatitis B virus and mixed connective tissue disease treated with prednisolone and chloroquine. J Clin Virol. 2004;31(1):53–57. doi: 10.1016/j.jcv.2004.02.013
  32. Ceballos-Viro J, López-Picazo JM, Pérez-Gracia JL, et al. Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer. World J Gastroenterol. 2009;15(18): 2290–2292. doi: 10.3748/wjg.15.2290
  33. Topaloglu S, Calik A, Kalayci O, et al. Fibrosing cholestatic hepatitis after methotrexate and prednisone therapy for rheumatoid arthritis. Exp Clin Transplant. 2014;12 Suppl. 1:95–97.
  34. Nassar AH, Abdul-Jawad BM, Barnes DS. Hepatic Failure Due to Cholestatic Hepatitis C in an Immunosuppressed Patient Treated With Elbasvir and Grazeprevir. ACG Case Reports Journal. 2018;5:e6. doi: 10.14309/crj.2018.6
  35. Morii K, Hatono T, Yokoyama M, et al., Fibrosing Cholestatic Hepatitis C in a Patient with Systemic Lupus Erythematosus. J Gastroenterol Hepatol Res. 2012;1(8):165–170.
  36. Saleh F, Ko HH, Davis JE, et al. Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis. Ann Hepatol. 2007;6(3):186–189.
  37. Pellicelli AM, D’ambrosio C, Dessanti ML, et al. Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma. Ann Hepatol. 2015;14(5):756–761.
  38. Chen CH, Chen PJ, Chu JS, et al. Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. Gastroenterology. 1994;107(5):1514–1518. doi: 10.1016/0016-5085(94)90557-6
  39. Hung YB, Liang JT, Chu JS, Chen KM, Lee CS. Fulminant hepatic failure in a renal transplant recipient with positive hepatitis B surface antigens: a case report of fibrosing cholestatic hepatitis. Hepatogastroenterology. 1995;42(6):913–918.
  40. Booth JC, Goldin RD, Brown JL, Karayiannis P, Thomas HC. Fibrosing cholestatic hepatitis in a renal transplant recipient associated with the hepatitis B virus precore mutant. J Hepatol. 1995.22(4):500–503. doi: 10.1016/0168-8278(95)80116-2
  41. Al Faraidy K, Yoshida EM, Davis JE, et al. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation. 1997;64(6): 926–928. doi: 10.1097/00007890-199709270-00024
  42. Lam PW, Wachs ME, Somberg KA, et al. Fibrosing cholestatic hepatitis in renal transplant recipients. Transplantation. 1996;61(3):378–381. doi: 10.1097/00007890-199602150-00008
  43. Brind AM, Bennett MK, Bassendine MF. Nucleoside analogue therapy in fibrosing cholestatic hepatitis — a case report in an HBsAg positive renal transplant recipient. Liver. 1998;18(2):134–139. doi: 10.1111/j.1600-0676.1998.tb00139.x
  44. Waguri N, Ichida T, Fujimaki R, et al. Fibrosing cholestatic hepatitis after living related-donor renal transplantation. J Gastroenterol Hepatol. 1998;13(11):1133–1137. doi: 10.1111/j.1440-1746.1998.tb00589.x
  45. Toth CM, Pascual M, Chung RT, et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation. 1998;66(9):1254–1258. doi: 10.1097/00007890-199811150-00023
  46. Chan TM, Wu PC, Li FK, et al. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology. 1998;115(1):177–181. doi: 10.1016/s0016-5085(98)70380-4
  47. Zylberberg H, Carnot F, Mamzer MF, et al. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation. Transplantation. 1997;63(1):158–160. doi: 10.1097/00007890-199701150-00029
  48. Muñoz De Bustillo E, Ibarrola C, Colina F, et al. Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant recipients. J Am Soc Nephrol. 1998;9(6):1109–1113. doi: 10.1681/ASN.V961109
  49. Delladetsima JK, Boletis JN, Makris F, et al. Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transpl Surg. 1999;5(4):294–300. doi: 10.1002/lt.500050417
  50. Delladetsima I, Psichogiou M, Sypsa V, et al. The course of hepatitis C virus infection in pretransplantation anti-hepatitis C virus-negative renal transplant recipients: a retrospective follow-up study. Am J Kidney Dis. 2006:47(2):309–316. doi: 10.1053/j.ajkd.2005.11.008
  51. Boletis JN, Delladetsima JK, Makris F, et al. Cholestatic syndromes in renal transplant recipients with HCV infection. Transpl Int. 2000;13 Suppl. 1:S375–S379. doi: 10.1007/s001470050365
  52. Hooda AK, Puri P, Narula AS, et al. Hepatitis C virus-related fibrosing cholestatic hepatitis in a renal transplant recipient. Indian J Gastroenterol. 2006;25(6):308–309.
  53. Shores NJ, Kimberly J. Seronegative hepatitis C-related fibrosing cholestatic hepatitis after renal transplant: a case report and review of the literature. NDT Plus. 2008;1(4):241–243. doi: 10.1093/ndtplus/sfn027
  54. Honsová E, Sperl J. Fibrotizující cholestatická hepatitida — onemocneni nejen transplantovaných pacientů. Ceskoslovenska patologie. 2011;47(2):55–58. (In Czech).
  55. Siddiqui AR, Abbas Z, Luck NH, et al. Experience of fibrosing cholestatic hepatitis with hepatitis C virus in kidney transplant recipients. Transplant Proc. 2012;44(3):721–724. doi: 10.1016/j.transproceed.2011.12.019
  56. Li DL, Fang J, Zheng Z, Wu W, Wu Z. Successful treatment of fibrosing cholestatic hepatitis following kidney transplantation with allogeneic hematopoietic stem cell transplantation: a case report. Medicine. 2015;94(5):e480. doi: 10.1097/MD.0000000000000480
  57. Shinzato T, Kubo T, Shimizu T, Nanmoku K, Yagisawa T. Fibrosing cholestatic hepatitis in a kidney transplant recipient with hepatitis C virus. CEN Case Reports. 2019;8(2):101–105. doi: 10.1007/s13730-018-0374-6
  58. Kapila N, Al-Khalloufi K, Bejarano PA, Vanatta JM, Zervos XB. Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: A unique complication in the DAA era. Am J Transplant. 2020;20(2):600–605. doi: 10.1111/ajt.15583
  59. Delgado J, Muñoz de Bustillo E, Ibarrola C, et al. Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor? J Heart Lung Transplant. 1999;18(6):607–610. doi: 10.1016/s1053-2498(98)00019-9
  60. Ong JP, Barnes DS, Younossi ZM, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology. 1999;30(5):1293–1298. doi: 10.1002/hep.510300519
  61. Liu CH, Chen YS, Wang SS, Kao JH. Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir. J Formos Med Assoc. 2017;116(5):407–409. doi: 10.1016/j.jfma.2016.12.005
  62. Mcivor C, Morton J, Bryant A, et al. Fatal reactivation of precore mutant hepatitis B virus associated with fibrosing cholestatic hepatitis after bone marrow transplantation. Ann Intern Med. 1994;121(4): 274–275. doi: 10.7326/0003-4819-121-4-199408150-00007
  63. Suresh RL, Merican I, Chang KM, Yong SM, Purusothaman V. Cholestatic fibrosing hepatitis and hepatitis B after bone marrow transplantation. The Medical Journal of Malaysia. 2001;56(4):508–511.
  64. Evans AT, Loeb KR, Shulman HM, Hassan S, Qiu WC, Hockenbery DM et al. Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases. The American Journal of Surgical Pathology. 2015;39(2):212–220. doi: 10.1097/PAS.0000000000000345
  65. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003;9(11):S1–S9. doi: 10.1053/jlts.2003.50268
  66. Verna EC, Abdelmessih R, Salomao MA, et al. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl. 2013;19(1):78–88. doi: 10.1002/lt.23559
  67. Moreira RK, Salomao M, Verna EC, Brown RS Jr, Lefkowitch JH. The Hepatitis Aggressiveness Score (HAS): a novel classification system for post-liver transplantation recurrent hepatitis C. The American Journal of Surgical Pathology. 2013;37(1):104–113. doi: 10.1097/PAS.0b013e31826a92ac
  68. Berenguer M, McCaughan G. Hepatitis C virus-associated cholestatic hepatitis: we cannot seem to agree on diagnostic criteria. Liver Transpl. 2013;19(2):115–117. doi: 10.1002/lt.23580
  69. Lucey MR, Graham DM, Martin P, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut. 1992;33(10):1390–1396. doi: 10.1136/gut.33.10.1390
  70. Voskanyan SE, Syutkin VE, Shabalin MV, et al. Seronegative fibrosing cholestatic hepatitis С after liver retransplantation for unresectable neuroendocrine tumor liver metastases. Transplantologiya. The Russian Journal of Transplantation. 2020;12(4):319–331. (In Russ). doi: 10.23873/2074-0506-2020-12-4-319-331
  71. McCaughan GW, Bowen DG. Pathogenesis of cholestatic hepatitis C. J Hepatol. 2011;54(2):392–394. doi: 10.1016/j.jhep.2010.09.010
  72. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl. 2010;16(11):1228–1235. doi: 10.1002/lt.22175
  73. Angus PW, Locarnini SA, McCaughan GW, et al. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology. 1995;21(1):14–18.
  74. Fang JW, Tung FY, Davis GL, et al. Fibrosing cholestatic hepatitis in a transplant recipient with hepatitis B virus precore mutant. Gastroenterology. 1993;105(3):901–904. doi: 10.1016/0016-5085(93)90910-5
  75. Bonino F, Brunetto MR. Hepatitis B virus heterogeneity, one of many factors influencing the severity of hepatitis B. J Hepatol. 1993;18(1):5–8. doi: 10.1016/s0168-8278(05)80003-0
  76. Cooksley WG, McIvor CA. Fibrosing cholestatic hepatitis and HBV after bone marrow transplantation. Biomed Pharmacother. 1995;49(3):117–124. doi: 10.1016/0753-3322(96)82604-7
  77. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49 Suppl. 5:S138–S145. doi: 10.1002/hep.22883
  78. Revill PA, Littlejohn M, Ayres A et al. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS. 2007;21(13):1701–1710. doi: 10.1097/QAD.0b013e32826fb305
  79. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood. 1994;84(4):1020–1023.
  80. Walsh KM, Woodall T, Lamy P, et al. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut. 2001;49(3):436–440. doi: 10.1136/gut.49.3.436
  81. Lo CM, Cheung ST, Ng IOL, et al. Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. Liver Transpl. 2004;10(4):557–563. doi: 10.1002/lt.20133
  82. Leroy V, Dumortier J, Coilly A, Sebagh M, Fougerou-Leurent C, Radenne S et al. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation. Clin Gastroenterol Hepatol. 2015;13(11):1993–2001. doi: 10.1016/j.cgh.2015.05.030
  83. Forns X, Mutimer D, Manns M, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation. J Hepatol. 2015;62 Suppl. 2:S623–S623. doi: 10.1016/S0168-8278(15)30982-X
  84. Pungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015;61(6):1880–1886. doi: 10.1002/hep.27770
  85. Merli M, Rossotti R, Travi G, et al. Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV. Transpl Infect Dis. 2019;21(6):e13165. doi: 10.1111/tid.13165
  86. Mauro E, Crespo G, Montironi C, et al. Viral eradication and fibrosis resolution in post-liver transplant cholestatic hepatitis C virus. Liver Transpl. 2018;24(5):703–707. doi: 10.1002/lt.25027
  87. Coilly A, Sebagh M, Fougerou-Leurent C, et al. HCV eradication does not protect from fibrosis progression in patients with fibrosing cholestatic hepatitis after liver transplantation. Clinics and Research in Hepatology and Gastroenterology. 2022;46(9):102024. doi: 10.1016/j.clinre.2022.102024

Copyright (c) 2024 Eco-vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies